<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-11T02:02:21Z</responseDate>
  <request identifier="oai:figshare.com:article/33811183" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/33811183</identifier>
        <datestamp>2026-09-15T17:36:43Z</datestamp>
        <setSpec>category_4</setSpec>
        <setSpec>category_7</setSpec>
        <setSpec>category_12</setSpec>
        <setSpec>category_13</setSpec>
        <setSpec>category_21</setSpec>
        <setSpec>category_106</setSpec>
        <setSpec>category_61</setSpec>
        <setSpec>category_62</setSpec>
        <setSpec>category_64</setSpec>
        <setSpec>category_132</setSpec>
        <setSpec>portal_5</setSpec>
        <setSpec>item_type_3</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>&lt;p&gt;Baseline characteristics of entrectinib-associated adverse event reports in the FAERS database.&lt;/p&gt;</dc:title>
          <dc:creator>JiaLe Yang (24948415)</dc:creator>
          <dc:creator>JiaWen Liu (24948418)</dc:creator>
          <dc:creator>GuanBo Zhao (24948421)</dc:creator>
          <dc:creator>HeChen Li (24948424)</dc:creator>
          <dc:creator>Ge Sun (332789)</dc:creator>
          <dc:subject>Biochemistry</dc:subject>
          <dc:subject>Medicine</dc:subject>
          <dc:subject>Cell Biology</dc:subject>
          <dc:subject>Genetics</dc:subject>
          <dc:subject>Biotechnology</dc:subject>
          <dc:subject>Science Policy</dc:subject>
          <dc:subject>Developmental Biology</dc:subject>
          <dc:subject>Marine Biology</dc:subject>
          <dc:subject>Cancer</dc:subject>
          <dc:subject>Infectious Diseases</dc:subject>
          <dc:subject>world reporting patterns</dc:subject>
          <dc:subject>whereas 58 pts</dc:subject>
          <dc:subject>reporting odds ratio</dc:subject>
          <dc:subject>molecular fusion status</dc:subject>
          <dc:subject>four disproportionality methods</dc:subject>
          <dc:subject>database pharmacovigilance study</dc:subject>
          <dc:subject>2020q1 &amp;# 8211</dc:subject>
          <dc:subject>related reporting heterogeneity</dc:subject>
          <dc:subject>weibull analysis suggested</dc:subject>
          <dc:subject>generating signals rather</dc:subject>
          <dc:subject>45 ), syncope</dc:subject>
          <dc:subject>45 ), myocarditis</dc:subject>
          <dc:subject>valid onset data</dc:subject>
          <dc:subject>xlink "&gt; entrectinib</dc:subject>
          <dc:subject>xlink "&gt; reports</dc:subject>
          <dc:subject>29 ), ataxia</dc:subject>
          <dc:subject>jader &lt;/ p</dc:subject>
          <dc:subject>xlink "&gt;</dc:subject>
          <dc:subject>related reports</dc:subject>
          <dc:subject>onset analysis</dc:subject>
          <dc:subject>43 ),</dc:subject>
          <dc:subject>35 ),</dc:subject>
          <dc:subject>23 signals</dc:subject>
          <dc:subject>evaluable reports</dc:subject>
          <dc:subject>associated reports</dc:subject>
          <dc:subject>520 reports</dc:subject>
          <dc:subject>urinary disorders</dc:subject>
          <dc:subject>safety profile</dc:subject>
          <dc:subject>positive non</dc:subject>
          <dc:subject>older patients</dc:subject>
          <dc:subject>nsclc ),</dc:subject>
          <dc:subject>median time</dc:subject>
          <dc:subject>including relatively</dc:subject>
          <dc:subject>identify cross</dc:subject>
          <dc:subject>female predominance</dc:subject>
          <dc:subject>explore age</dc:subject>
          <dc:subject>evaluate time</dc:subject>
          <dc:subject>characterize real</dc:subject>
          <dc:subject>based time</dc:subject>
          <dc:subject>92 ).</dc:subject>
          <dc:subject>63 ).</dc:subject>
          <dc:subject>573 preferred</dc:subject>
          <dc:subject>520 patients</dc:subject>
          <dc:subject>254 patients</dc:subject>
          <dc:subject>0 %)</dc:subject>
          <dc:description>&lt;p&gt;Baseline characteristics of entrectinib-associated adverse event reports in the FAERS database.&lt;/p&gt;</dc:description>
          <dc:date>2026-09-15T17:36:21Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Dataset</dc:type>
          <dc:identifier>10.1371/journal.pone.0358331.t001</dc:identifier>
          <dc:relation>https://figshare.com/articles/dataset/_p_Baseline_characteristics_of_entrectinib-associated_adverse_event_reports_in_the_FAERS_database_p_/33811183</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
